New hope for rare cancer: drug combo shows promise in advanced angiosarcoma

NCT ID NCT01303497

Completed Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding a targeted drug called bevacizumab to standard chemotherapy (paclitaxel) helps control advanced angiosarcoma, a rare cancer of blood vessels. About 70 adults whose cancer had spread or could not be removed by surgery took part. The goal was to see if the combination could stop the cancer from growing for at least 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

angiosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANGIOSARCOMA

Contacts and locations

Locations

Centre Antoine Lacassagne

Nice, 06189, France
Centre François Baclesse

Caen, 14076, France
Centre Georges François Leclerc

Dijon, 21079, France
Centre Jean Perrin

Clermont-Ferrand, 63011, France
Centre Léon Bérard

Lyon, 69008, France
Centre Oscar Lambret

Lille, 59020, France
Centre René Gauducheau

Saint-Herblain, 44805, France
Centre Val d'Aurelle

Montpellier, 34298, France
Institut Bergonié

Bordeaux, 33076, France
Institut Claudius Regaud

Toulouse, 31052, France
Institut Curie

Paris, 75005, France
Institut Gustave Roussy

Villejuif, 94805, France
Institut de Cancérologie de la Loire

Saint-Priest-en-Jarez, 42270, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.